ADMA BIOLOGICS, INC.
ADMA evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Market Cap:
- $2.14B
- Lead Asset:
- ASCENIV (Approved)
What it means
What to watch
Prepared research question
What matters most for ADMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADMA
ADMA Biologics, Inc. is a U.S.-based commercial biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics, with three FDA-approved products including its lead IVIG therapy ASCENIV for primary immunodeficiency.
Key risk: High debt level
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 6 clinical trials for ADMA BIOLOGICS, INC..
ADMA Biologics, Inc. is a U.S.-based commercial biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics, with three FDA-approved products including its lead IVIG therapy ASCENIV for primary immunodeficiency.
- ADMA has three FDA-approved, commercially available products: ASCENIV (IVIG for primary immunodeficiency), BIVIGAM, and an additional approved product [sec_mda · as of 2026-05-06].
- FY 2025 total revenue reached $510 million, representing 20% year-over-year growth, with ASCENIV revenue growing 51% to $363 million [news · published 2026-02-26].
- As of 2026-06-30, the company reported cash & equivalents of $136.0M, total revenue of $124.4M, net income of $37.8M, shareholders' equity of $408.2M, and total debt of $198.1M [sec].
- ADMA is advancing an innovative yield enhancement production process (submitted as a Prior Approval Supplement to the FDA) that has demonstrated the ability to increase production yields by approximately 20% from the same starting plasma volume [sec · filed 2025-04-15].
- The company acquired real estate in Boca Raton, FL in July 2025 for $12.6 million to expand production capacity, cold storage, warehousing, and in-house testing capabilities [sec_mda · as of 2026-02-25].
What works
- Strong revenue growth trajectory: FY 2025 total revenue grew 20% year-over-year to $510M, with ASCENIV revenue up 51% to $363M [news · published 2026-02-26].
- Vertically integrated U.S.-based supply chain with recent capacity expansion investments, including a land acquisition that potentially provides for up to 30% in future cGMP capacity expansion [sec · filed 2026-04-15].
- Innovative yield enhancement process (submitted to FDA) could increase production yields by ~20% from the same starting plasma volume, improving margins and supply [sec · filed 2025-04-15].
- Multiple long-term high-titer plasma supply contracts with third parties, sourcing from approximately 250 collection centers, securing raw material for ASCENIV production [sec · filed 2025-04-15].
What to weigh
- Significant debt load: total debt of $198.1M as of 2026-06-30, which could constrain financial flexibility [sec].
- Dependence on a single lead product: ASCENIV accounted for $363M of $510M total revenue in FY 2025, making the company highly reliant on its IVIG franchise [news · published 2026-02-26].
- Regulatory and operational risks associated with the yield enhancement process: the FDA approval timeline is uncertain and any delay or denial could impact growth plans [sec · filed 2025-04-15].
- Long production cycle time: end-to-end production from raw material procurement to commercial release can take between seven and an unspecified number of months, creating working capital and inventory risk [sec_mda · as of 2026-02-25].
From the filings
Quoted directly from source documents.
FY 2025 total revenue was $510 million, up 20% year-over-year.
“FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth”
News · February 26, 2026
Yield enhancement process could increase production yields by approximately 20%.
“a Prior Approval Supplement for potential approval of an innovative yield enhancement production process to the U.S. Food and Drug Administration (the "FDA"), which has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume.”
SEC filings · April 15, 2025
Land acquisition in Boca Raton for capacity expansion.
“In July 2025, we completed the acquisition of real estate in Boca Raton, FL for a total purchase price of $12.6 million.”
SEC MD&A · February 25, 2026
Catalyst timeline
- 2018-12-07 · Phase2_Start: EFFORT: Efficacy of AZD1775 in Parp Resistance — A randomized Phase 2 study of AZD1775 alone or with olaparib in ovarian cancer patients who progressed during PARP inhibition.
- 2024-03-11 · AdCom: BIVIGAM — Advisory committee meeting for BIVIGAM.
- 2024-03-11 · AdCom: ASCENIV — Advisory committee meeting for ASCENIV.
- 2025-04-01 · Phase3_Start: INSIGHT — Randomized Phase III trial incorporating pathologic complete response in early-stage non-small cell lung cancer to optimize immunotherapy in the adjuvant setting.
- 2025-04-28 · AdCom: innovative production yield enhancement process — Advisory committee meeting for the innovative production yield enhancement process.
- 2026-05-31 · Phase1_Start: Amicidin-β Topical Solution — Phase 1 study to assess safety and tolerability of Amicidin-β Topical Solution in adult patients undergoing...
Risks & what to watch (4)›
Key risks
- High debt level — Total debt of $198.1M as of 2026-06-30 may limit financial flexibility and increase interest expense [sec].
- Product concentration risk
- Regulatory approval uncertainty
- Long production cycle
What to watch
- FDA decision on the Prior Approval Supplement for the yield enhancement production process, which could increase yields by ~20% [sec · filed 2025-04-15].
- Commercial adoption and revenue growth of ASCENIV, particularly in the primary immunodeficiency market [news · published 2026-02-26].
- Progress of the SG-001 pipeline program and any clinical updates [news · published 2026-02-26].
- Integration and utilization of the new Boca Raton facility for capacity expansion and operational efficiencies [sec_mda · as of 2026-02-25].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run ADMA BIOLOGICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ADMA BIOLOGICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.68 · 1% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
356
Total value held
$1.85B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 36,830,774 | $331.8M |
| state street corp | 14,084,205 | $126.9M |
| capital research global investors | 11,191,116 | $100.8M |
| vanguard capital management llc | 10,306,871 | $92.9M |
| vanguard portfolio management llc | 8,868,657 | $79.9M |
| nuveen, llc | 6,098,225 | $54.9M |
| geode capital management, llc | 5,824,116 | $52.5M |
| citadel advisors llc | 5,810,642 | $52.4M |
| dimensional fund advisors lp | 5,005,481 | $45.1M |
| american century companies inc | 4,789,011 | $43.1M |
Showing top 10 of 356 institutional holders of ADMA BIOLOGICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 11.7%
- Days to cover
- 2.5
- Shares short
- 22,175,506
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADMA short interestGovernance
Frequently asked questions
What is the AI investment thesis for ADMA BIOLOGICS, INC.?
ADMA Biologics, Inc. is a U.S.-based commercial biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived biologics, with three FDA-approved products including its lead IVIG therapy ASCENIV for primary immunodeficiency.
What is ADMA BIOLOGICS, INC.'s lead drug candidate?
ADMA BIOLOGICS, INC.'s most advanced tracked candidate is ASCENIV (Approved) for Treatment of Primary Humoral Immunodeficiency (PI) / Primary Immunodeficiency Disease (PIDD) in adults and adolescents (12 to 17 years of age).
Who is the CEO of ADMA BIOLOGICS, INC.?
Mr. Adam S. Grossman is the chief executive officer of ADMA BIOLOGICS, INC. (ADMA).
Where is ADMA BIOLOGICS, INC. headquartered?
ADMA BIOLOGICS, INC. (ADMA) is headquartered in Ramsey, NJ, United States.
What therapeutic areas does ADMA BIOLOGICS, INC. focus on?
ADMA BIOLOGICS, INC. develops therapies across Oncology, Immunology, Metabolic, Dermatology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.